Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204775 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 16
- Study locations
NCT01204775 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 26 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 16 study locations across 7 states.
The verdict
NCT01204775, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Saxagliptin
- DRUG Metformin IR
- DRUG Placebo (Saxagliptin)
- DRUG Placebo (Metformin)
- DRUG Metformin (Active Rescue)
Study Locations (16)
Other
- Research Site - Moscow
- Research Site - Novosibirsk
- Research Site - Saint Petersburg
- Research Site - Cape Town
- Research Site - Pretoria
- Research Site - Taichung
- Research Site - Taipei
Florida
- Research Site - Hollywood
- Research Site - Tallahassee
- Research Site - Tampa
California
- Research Site - Los Angeles
- Research Site - San Diego
Michigan
- Research Site - Dearborn
New York
- Research Site - Buffalo
Tennessee
- Research Site - Memphis
Virginia
- Research Site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204775
The ClinicalTrials.gov registry entry for NCT01204775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 5 interventions - of which Saxagliptin is the first listed.
NCT01204775 reports 16 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT01204775 about?
NCT01204775 is a clinical study titled "Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.
What is the current status of trial NCT01204775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2011-06. Estimated completion is 2016-04.
What conditions does trial NCT01204775 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT01204775?
The interventions under investigation include: Saxagliptin (DRUG), Metformin IR (DRUG), Placebo (Saxagliptin) (DRUG), Placebo (Metformin) (DRUG), Metformin (Active Rescue) (DRUG).
Who is sponsoring clinical trial NCT01204775?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01204775 being conducted?
This trial has 16 study locations across California, Florida, Michigan, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.